» Articles » PMID: 29218016

Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin

Overview
Journal Front Physiol
Date 2017 Dec 9
PMID 29218016
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Developing effective and safe anti-AF drugs remains an unmet challenge. Simultaneous block of both atrial-specific ultra-rapid delayed rectifier potassium (K) current (I) and the Na current (I) has been hypothesized to be anti-AF, without inducing significant QT prolongation and ventricular side effects. However, the antiarrhythmic advantage of simultaneously blocking these two channels vs. individual block in the setting of AF-induced electrical remodeling remains to be documented. Furthermore, many I blockers such as acacetin and AVE0118, partially inhibit other K currents in the atria. Whether this multi-K-block produces greater anti-AF effects compared with selective I-block has not been fully understood. The aim of this study was to use computer models to (i) assess the impact of multi-K-block as exhibited by many I blokers, and (ii) evaluate the antiarrhythmic effect of blocking I and I, either alone or in combination, on atrial and ventricular electrical excitation and recovery in the setting of AF-induced electrical-remodeling. Contemporary mathematical models of human atrial and ventricular cells were modified to incorporate dose-dependent actions of acacetin (a multichannel blocker primarily inhibiting I while less potently blocking I, I, and I). Rate- and atrial-selective inhibition of I was also incorporated into the models. These single myocyte models were then incorporated into multicellular two-dimensional (2D) and three-dimensional (3D) anatomical models of the human atria. As expected, application of I blocker produced pronounced action potential duration (APD) prolongation in atrial myocytes. Furthermore, combined multiple K-channel block that mimicked the effects of acacetin exhibited synergistic APD prolongations. Synergistically anti-AF effects following inhibition of I and combined I/K-channels were also observed. The attainable maximal AF-selectivity of I inhibition was greatly augmented by blocking I or multiple K-currents in the atrial myocytes. This enhanced anti-arrhythmic effects of combined block of Na- and K-channels were also seen in 2D and 3D simulations; specially, there was an enhanced efficacy in terminating re-entrant excitation waves, exerting improved antiarrhythmic effects in the human atria as compared to a single-channel block. However, in the human ventricular myocytes and tissue, cellular repolarization and computed QT intervals were modestly affected in the presence of actions of acacetin and I blockers (either alone or in combination). In conclusion, this study demonstrates synergistic antiarrhythmic benefits of combined block of I and I, as well as those of I and combined multi K-current block of acacetin, without significant alterations of ventricular repolarization and QT intervals. This approach may be a valuable strategy for the treatment of AF.

Citing Articles

Mechanistic insight into the functional role of human sinoatrial node conduction pathways and pacemaker compartments heterogeneity: A computer model analysis.

Zhao J, Sharma R, Kalyanasundaram A, Kennelly J, Bai J, Li N PLoS Comput Biol. 2023; 19(12):e1011708.

PMID: 38109436 PMC: 10760897. DOI: 10.1371/journal.pcbi.1011708.


Computational Modeling of Cardiac Electrophysiology.

Ni H, Grandi E Methods Mol Biol. 2023; 2735:63-103.

PMID: 38038844 DOI: 10.1007/978-1-0716-3527-8_5.


Multiplatform modeling of atrial fibrillation identifies phospholamban as a central regulator of cardiac rhythm.

Kervadec A, Kezos J, Ni H, Yu M, Marchant J, Spiering S Dis Model Mech. 2023; 16(7).

PMID: 37293707 PMC: 10387351. DOI: 10.1242/dmm.049962.


Common Structural Pattern for Flecainide Binding in Atrial-Selective K1.5 and Na1.5 Channels: A Computational Approach.

Mazola Y, Marquez Montesinos J, Ramirez D, Zuniga L, Decher N, Ravens U Pharmaceutics. 2022; 14(7).

PMID: 35890252 PMC: 9318806. DOI: 10.3390/pharmaceutics14071356.


Acacetin as a Potential Protective Compound against Cardiovascular Diseases.

Wu C, Yan J, Li W Evid Based Complement Alternat Med. 2022; 2022:6265198.

PMID: 35280514 PMC: 8906942. DOI: 10.1155/2022/6265198.


References
1.
Koskinas K, Fragakis N, Katritsis D, Skeberis V, Vassilikos V . Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace. 2014; 16(7):973-9. DOI: 10.1093/europace/eut407. View

2.
Caves R, Cheng H, Choisy S, Gadeberg H, Bryant S, Hancox J . Atrial-ventricular differences in rabbit cardiac voltage-gated Na currents: Basis for atrial-selective block by ranolazine. Heart Rhythm. 2017; 14(11):1657-1664. PMC: 5666337. DOI: 10.1016/j.hrthm.2017.06.012. View

3.
Narayan S, Franz M, Clopton P, Pruvot E, Krummen D . Repolarization alternans reveals vulnerability to human atrial fibrillation. Circulation. 2011; 123(25):2922-30. PMC: 3135656. DOI: 10.1161/CIRCULATIONAHA.110.977827. View

4.
Grandi E, Pandit S, Voigt N, Workman A, Dobrev D, Jalife J . Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation. Circ Res. 2011; 109(9):1055-66. PMC: 3208665. DOI: 10.1161/CIRCRESAHA.111.253955. View

5.
Van Wagoner D, Pond A, McCarthy P, Trimmer J, Nerbonne J . Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res. 1997; 80(6):772-81. DOI: 10.1161/01.res.80.6.772. View